BioSpace News Archive

PointClickCare Technologies today announced a strategic collaboration with Pfizer Inc. to provide real world insights into the population at high risk of age-related disorders, which is aligned with PointClickCare’s mission to protect and support the senior population.

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

Galecto, Inc. announced its operating and financial results for the quarter ended September 30, 2022.

Kardium Inc. announces the successful first-in-human study of its next generation Globe® Pulsed Field System to treat atrial fibrillation (AF) using pulsed field ablation (PFA) therapy.

OMNIVISION today announced the OH02B image sensor – the first square 2-megapixel (MP) (1500x1500) resolution CMOS image sensor for gastrointestinal, ENT, orthopedic, surgical, dental, and veterinarian reusable and disposable endoscopes, catheters, and guide wires. It is available in the smallest form factor 2.5x2.5mm CameraCubeChip® package (OCH2B) for disposable designs.

BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced it has closed a CHF 20 million (approx. USD 20 million) financing round.

global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an international biopharmaceutical group specialising in structure-based drug design targeting G protein-coupled receptors (GPCRs).

KYOCERA AVX, a leading global manufacturer of advanced electronic components engineered to accelerate technological innovation and build a better future, is exhibiting at electronica 2022 in Munich, Germany, November 15–18.

Immune-Onc Therapeutics, Inc. today announced the appointments of Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. to the company’s board of directors.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results and business updates for the third quarter ending September 30, 2022. For the quarter ending September 30, 2022, Revenue was $7.0 million, Total Operating Expenses (Research and Development and General and Administrative) were $50 million, and Net Loss was $41.4 million. The Company provided a clinical update earlier today which is available here: https://bit.ly/3TYsqcZ.